The potential for liquid biopsies in the precision medical treatment of breast cancer. by Forte, Victoria A et al.
UC Office of the President
Recent Work
Title
The potential for liquid biopsies in the precision medical treatment of breast cancer.
Permalink
https://escholarship.org/uc/item/2084b6pq
Journal
Cancer biology & medicine, 13(1)
ISSN
2095-3941
Authors
Forte, Victoria A
Barrak, Dany K
Elhodaky, Mostafa
et al.
Publication Date
2016-03-01
DOI
10.28092/j.issn.2095-3941.2016.0007
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
REVIEW
The potential for liquid biopsies in the precision medical
treatment of breast cancer
Victoria A. Forte1,2, Dany K. Barrak2,3, Mostafa Elhodaky2,4, Lily Tung2,3, Anson Snow1,2, Julie E. Lang2,3
1Department of Medicine, Division of Medical Oncology, University of Southern California (USC), Los Angeles, CA 90033,
USA; 2USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA; 3Department of Surgery, Division of Breast,
Endocrine and Soft Tissue Surgery, USC, Los Angeles, CA 90033, USA; 4Department of Stem Cell and Regenerative Medicine,
USC, Los Angeles, CA 90033, USA
 
ABSTRACT Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen
receptor, progesterone receptor, HER2), based on primary tumor biology. Circulating biomarkers, such as circulating tumor DNA
(ctDNA) or circulating tumor cells (CTCs) may enhance our treatment options by focusing on the very cells that are the direct
precursors of distant metastatic disease, and probably inherently different than the primary tumor's biology. To shift the current
clinical paradigm, assessing tumor biology in real time by molecularly profiling CTCs or ctDNA may serve to discover therapeutic
targets,  detect  minimal  residual  disease  and predict  response  to  treatment.  This  review serves  to  elucidate  the  detection,
characterization, and clinical application of CTCs and ctDNA with the goal of precision treatment of breast cancer.
KEYWORDS Circulating tumor cells (CTCs); circulating tumor DNA (ctDNA); cell free DNA (cfDNA); biomarker; cancer
 
Introduction
The  concept  of  personalized  medicine  in  oncology,  or
customizing cancer treatment based on specific biomarkers
predictive of drug response, is rapidly progressing based on
innovative  translational  research  strategies  and  the
implementation of biomarkers in clinical trial design. The
key to personalizing medicine is to identify biomarkers which
are  easily  accessible  and  could  be  repeatedly  accessed  to
inform  physicians  about  an  individual's  tumor  biology,
predict which therapeutic interventions may be of greatest
benefit,  monitor  treatment responses  to therapy,  identify
mechanisms of therapeutic resistance to guide subsequent
therapies, and assay for microscopic relapse1.
Primary tumor gene expression profiling is prognostic in
terms of probability of recurrence; however, breast cancer
patients would benefit greatly from a blood test that could
provide a real time assessment of the cancer cells  that are
most likely to produce distant metastatic disease. Circulating
biomarkers  may provide insights  into how to better  treat
breast cancer patients by focusing on the very cells that are
the  direct  precursors  of  distant  metastatic  disease,  and
probably very different than the primary tumor's biology.
Two  circulating  biomarkers  through  which  personalized
medicine can be achieved are the study of circulating tumor
cells (CTCs) and that of circulating tumor DNA (ctDNA).
These  have  been  promoted  as  potential  real  time  "liquid
biopsies",  minimally  invasive  biomarkers  capable  of
providing a  global  picture  of  the  tumor burden and vital
genetic information about the targeted tumor from a blood
draw2-4. However, challenges still remain in the identification,
isolation, and ultimate harnessing of these methodologies in
order to effectively guide treatment. This review serves to
identify the detection, characterization, and application of
ctDNA and CTCs with the goal  of  precision treatment of
breast cancer.
CTCs
CTCs are recognized to be rare cells that are shed from the
primary or metastatic tumor and can be isolated from the
peripheral blood of patients with solid and liquid tumors5.
CTCs were first reported in 1869 in the blood of a man with
metastatic  cancer  by  scientist  Thomas  Ashworth,  who
performed a thorough comparison of the morphology of the
  
Correspondence to: Julie E. Lang
E-mail: julie.lang@med.usc.edu
Received January 8, 2016; accepted March 8, 2016.
Available at www.cancerbiomed.org
Copyright © 2016 by Cancer Biology & Medicine
Cancer Biol Med 2016. doi: 10.28092/j.issn.2095-3941.2016.0007
circulating cells to tumor cells leading him to conclude that
"one  thing  is  certain,  that  if  they  (CTCs)  came  from  an
existing cancer structure, they must have passed through the
greater  part  of  the  circulatory  system"6,7.  CTCs  are  an
independent prognostic factor in all stages of breast cancer8-
12.  CTC's rarity and short  half-life,  probably measured in
hours, renders isolation a challenge; therefore a successful
assay should ideally be able to process a large amount of cells
in  a  relatively  short  amount  of  time  while  being  able  to
specifically enumerate and capture malignant cells from a
vast blood background - requiring the ability to detect one
CTC per 105-107 mononuclear cells13. Such assays include a
large panel of technologies based on their multiple physical
and biological properties such as size, deformability, surface
protein expression, viability, and invasion capacity properties
distinguishing them from the surrounding hematopoietic cell
lineage5,14.  Our group has previously reviewed the state of
this  scientific  field  and speculated that  CTCs would gain
considerable interest as molecular techniques that allowed for
their characterization developed and could permit translation
to the clinic15.
CTCs  have  been  molecularly  profiled  via  several
approaches,  including  using  next-generation  sequencing
(NGS)16,17. These advances have revealed some mechanisms
of  drug  resistance  including  epithelial  to  mesenchymal
transition (EMT)18-20. In addition, these breakthroughs can
help us characterize those cancer cells capable of metastasis
and  optimize  targeted  therapies  based  on  each  patient's
unique tumor biology, not simply rely on the standard four
therapeutic groups of breast cancer: (1) hormone receptor
(HR)  positive  patients  who  have  estrogen  and/or
progesterone-dependent  tumors  but  are  HER2  (human
epidermal growth factor type 2) negative (ER/PR+HER2−);
(2) HR positive and HER2 positive (ER/PR+HER2+) patients
who  have  amplification  or  overexpression  of  HER2,  in
addition to estrogen and/or progesterone-dependent tumors;
(3)  HR  negative  group  with  HER2  overexpression/
amplification  (ER/PR−HER2+),  and  (4)  triple-negative
breast  cancers  (TNBCs),  which  are  defined  by  a  lack  of
expression  of  ER,  PR,  and  HER221,22.  Optimization  of
detection  techniques  is  required  in  order  to  molecularly
characterize CTCs and incorporate this information into the
current clinical landscape.
CTC detection techniques
Over the last two decades there have been several methods
developed for isolating and analyzing CTCs.  Overall  they
may  be  separated  into  affinity  based,  physical  properties
based, and functional assays. Many affinity-based techniques
isolate cells based on expression of cell-surface markers, such
as  the  epithelial  cell  adhesion  molecule  (EpCAM),  and
include the CellSearch assay (the only FDA approved method
of detecting CTCs in breast cancer), the Herringbone-CTC
chip, and flow cytometry-based approaches. Many of these
selection technologies are criticized for their reliance on cell-
surface expression of EpCAM to capture (and define) CTCs
because  some  tumors  down-regulate  expression  of  this
marker during EMT. In addition, preanalytic variables, such
as time to assay are significant factors in CTC detection and
may be more important than EpCAM high status, with the
exception of claudin low tumors23. To address this limitation,
physical  property and functional  based technologies  have
been developed that isolate CTCs on the basis of physico-
chemical  properties-such as size,  density,  surface charges,
unique functional characteristics-that distinguish them from
other blood cells24. Please see Table 1 for a summary of the
various isolation techniques being utilized25-93.
Additionally, there are various pre-analytical conditions to
take into consideration such as the time interval  between
blood draw and assay, type of tube utilized, use of fixatives or
preservatives, and temperature. Our group has focused on
pre-analytic  variables  pertaining  to  the  amplification  of
picogram quantities of  RNA as well  as  time to CTC assay
influencing the number of cells recovered23,94.
EMT
According to recent findings, more invasive CTCs may lose
their  epithelial  antigens  by  the  EMT  process,  rendering
detection  via  EpCAM  based  technologies  challenging.
Through  the  EMT  process,  epithelial  cells  lose  cell-cell
contacts and cell polarity, downregulate epithelial-associated
genes, acquire mesenchymal gene expression, and undergo
major changes in their  cytoskeleton. This cellular process
culminates  in  a  mesenchymal  appearance  and  increased
motility and invasiveness95,96.
In the actuation of the EMT program, epithelial markers
such  as  E-cadherin  and  cytokeratins  are  downregulated,
whereas  mesenchymal  markers,  such  as  vimentin  and
fibronectin  are  frequently  overexpressed.  Furthermore,
intermediate  phenotypes  between  epithel ia l  and
mesenchymal  differentiation  are  described  to  co-exist  in
human cancer97.  Cancer  cells  can be  induced to  undergo
EMT  by  several  signaling  pathways,  most  notably  those
involving the cooperation between TGF-β  1 signaling and
oncogenic RAS or other receptor tyrosine kinases, as well as
Wnt,  Notch,  and  the  signaling  activated  by  Hedgehog98,
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Table 1  A summary of the various isolation techniques being utilized
Technique Description Reference
Physical properties based
assays
Dean Flow Fractionation
(DFF)
The device maintains to process 3 mL of whole blood in an hour using centrifugal forces with
>90% CTC recovery. The continuous collection of sorted CTCs and short residence time in the
device significantly shortens the CTCs exposure time to constant shear in the channel, thus
minimizing any undesirable shear induced changes to the CTCs' phenotype.
25
Cell density-based
enrichment
Density gradient separation of CTCs from other cells in the blood may be performed using
commercially available density gradient liquid separation kits. This process generates a
layered separation of cell types based on their density. Limitations include a possible loss of
CTCs due to an unwanted migration into the plasma fraction, as well as the formation of
nonspecific aggregates containing CTCs at the bottom of the gradient.
26-28
Size-based cell enrichment
by filtration
Direct enrichment of epithelial cells by filtration is based on the observation that the vast
majority of peripheral blood cells are among the smallest cells in the human body. They can
be eliminated by blood filtration using polycarbonate membrane calibrated pore filters. This
method is quite simple, involving one single step.
29-34
Selective size amplification
(SSA)
It offers advantages not only in resolving the trade-off between recovery rate and
purity—optimizing both—but also in reducing the mechanical stress exerted upon the CTCs
during filter transit. The major reasons for this enhanced performance include distinctive size
discrimination between WBCs and CTCs as well as the benefits of the solid microbeads
mitigating cell deformation within the MOA filter gap.
35
3D microfiltration This device consists of two parylene membrane layers with pores and a gap precisely defined
by photolithography. The positions of the pores are shifted between the top and bottom
membranes. The bottom membrane supports captured cells and minimizes stress, which is
concentrated on the cell membrane and sustains cell viability during filtration under very low
pressure.
36
ISET (isolation by size of
epithelial tumor cells)
Size-based enrichments of CTCs have been described by membrane filter devices such as ISET. 29,30,37
NanoVelcro CTC Chip By switching device temperature in a physiologically endurable range (i.e. 4-37°C),
thermoresponsive conformational changes of nanosubstrate-grafted polymer brushes alter
the accessibility of capture agent to specifically capture (37°C) and release (4°C) CTCs to give
viable CTCs in desired purity.
38
Telomescan A novel cancer detection platform that measures telomerase activity from viable CTCs
captured on a parylene-C slot microfilter. Using a constant low pressure delivery system, the
new microfilter platform is capable of cell capture from 1 mL of whole blood in less than 5
min, achieving 90% capture efficiency. Addition of an adenovirus-containing GFP to peripheral
blood assay, incubation with cancer cells allows precise enumeration and visualization of
CTCs.
39,40
Affinity based assays
CellSearch The only FDA-approved technology for CTC detection is based on immunomagnetic
enrichment. It employs an immunomagnetic enrichment step to isolate cells that express the
epithelial cells’ adhesion molecule (EpCAM). Additionally, to be identified as a CTC, the cell
must contain a nucleus, express cytoplasmic cytokeratin, and have a diameter larger than 5
μm. This technology has demonstrated the prognostic utility of enumerating and monitoring
CTC counts in patients with metastatic breast, prostate, and colorectal cancers.
Semiautomated analyzer enriches CTCs with ferrofluid nanoparticles coated with anti-EpCAM
antibodies, then CD45-, CK8+, CK18+ and CK19+ cells are counted by a four-color
semiautomated fluorescence microscope.
41-47
Table 1 (continued)
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Table 1 (continued)
Technique Description Reference
CTC-chip Capture of CTCs by EpCAM-coated microposts under strict manipulation of velocity and shear
force. It enables a high yield of capture (median, 50 CTCs per milliliter) and purity (ranging
from 10% to 50%), most likely caused by the gentle one-step microfluidic processing.
Captured cells remain viable after capture, although the absence of cell fixation currently
limits the time allowed between blood collection and microfluidic analysis to a few hours.
Captured CTCs are visualized by staining with antibodies against cytokeratin or tissue-specific
markers. For CTC enumeration, the entire device is imaged at multiple planes using a
semiautomated imaging system while on-chip lysis allows for DNA and RNA extraction and
molecular analyses. Nuclear fluorescence and CK stain for positive selection and CD45 stain
for negative selection; CTCs captured are directly recognized by cameras, based on
morphology, viability and expression of tumor markers. It has a total of 98% cell viability and
high detection rate, making further analysis possible.
48-51
Herringbone-chip Its chambers were made of transparent materials, allowing imaging of the captured CTCs,
using traditional histopathological stains, transmitted light microscopy and
immunofluorescence-conjugated antibodies. The Herringbone-chip has been tested in
metastatic prostate and lung cancer patients, verifying results with those obtained with the
CTC-chip method of analysis: Herringbone-chip shows higher flow rates and higher CTC
capture efficiency and purity.
52,53
AdnaTest Immunomagnetic separation with EpCAMs and MUC1 coupled antibodies; further analysis by
isolation, direct lysis, mRNA extraction and application of multiplexed RT-PCR for HER2,
EpCAM and MUC-1. Possibility to characterize CTCs for stem cells and epithelial mesenchymal
transition. It lacks flexibility and automation. Cannot enumerate cells due to lysis. False-
positive results due to the expression of the same antigens on nontumor cells; false-negative
results due to loss of antigens on CTCs.
54-58
EPISPOT (Epithelial
ImmunoSPOT)
Detects only viable cells after the depletion of CD45- positive cells, and was introduced for
CTC analyses. Avoiding direct contact with the target cells, this technique assesses the
presence of CTCs based on secreted or released proteins during 48h of short-term culture.
59,60
Collagen Adhesion Matrix
(CAM) assay
It has been reported in breast, prostate and ovarian cancer: CAM ingestion and epithelial
immunostaining identifies CTCs based on their invasive properties in vitro.
61
MAINTRAC A specialized laser scanning cytometer provides another EpCAM-based approach. 62
Biocept Utilizes proprietary antibody based enrichment technique to detect rare CTCs found in a
patient’s blood sample (1 in 1 million).
63
Photoacoustic flowmetry Making use of the broadband absorption spectrum of melanin, it has been tested to detect
melanoma cells and has been combined with nanoparticles targeting cell surface antigens to
broaden its applicability in CTC detection.
64,65
MagSweeper A magnetic stir bar coated with an antibody to EpCAM. The device can process 9 mL of blood
per hour and purified cells of interest can be individually selected for subsequent molecular
analysis, since the MagSweeper technology preserves cell function and does not perturb gene
expression.
66-70
DEPArray (Silicon
Biosystems)
An automated system with fluorescence imaging that captures cells in a chip based upon
electric movement. DEPArray achieved 100% purity, eliminating all white blood cells (WBC), in
the isolation of a mixed population of tumor cell lines downstream of CellSearch enrichment.
This enabled molecular profiling of pure tumor cells from whole blood spiked tumor cell lines.
71
CTC-iChip Whole blood is now processed through a microscale system at speeds of 8 mL/hour while
preserving the high sensitivity afforded by microfluidic isolation techniques. Furthermore,
rapid and gentle isolation of CTCs, as well as their collection in suspension, increases the
integrity of these cells and their RNA quality. Moreover, the system can be run in either a
positive selection or a negative depletion mode. The robustness of this platform was
demonstrated by staining CTCs per clinical pathology protocols, which yielded high-quality
diagnostic images. The negCTC-iChip allowed for isolation of CTCs from a nonepithelial
cancer (melanoma) and from cancer that has undergone EMT and lost virtually all detectable
EpCAM expression (TNBC). Limitations: low CTC purity to facilitate routine molecular analyses
of CTCs and total blood volume needed to enable early cancer detection.
72
Table 1 (continued)
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Table 1 (continued)
Technique Description Reference
Negative depletion CTC
enrichment strategy
Relies on the removal of normal cells using immunomagnetic separation in the blood of
cancer patients. This method is based on the combination of magnetic and fluid forces in an
axial, laminar flow in long cylinders placed in quadrapole magnets.
73
Millennium Sciences
IsoFlux
The blood is centrifuged. Immunomagnetic particles are added to the PMBC layer that target
the cells of interest. It is then transferred into a microfluidic cartridge. A permanent magnet is
placed on the roof of the channel to attract the labeled target cells.
74
Cynvenio Liquid Biopsy
platform
This platform uses high throughput sheath flow microfluidics for the positive selection of CTC
populations. Furthermore the platform quantitatively isolates cells useful for molecular
methods such as detection of mutations in 50 oncogenes.
75
Photoacoustic flowmetry Making use of the broadband absorption spectrum of melanin, it has been tested to detect
melanoma cells and has been combined with nanoparticles targeting cell surface antigens to
broaden its applicability in CTC detection.
64,65
Cytometric assays
FACS (Fluorescence-
activated cell sorting)
It enables simultaneous analysis of multiparameters, such as size, viability, DNA content and
expression of different markers for CTCs detection. It has high specificity, but low sensitivity.
76-79
Slide-based automated
scanning microscopes
(Ikoniscope and Ariol)
Maximizes scanner utilization with brightfield-multi-channel fluorescent and FISH capture
capabilities. Introduced for detecting CTCs; still need to be validated.
80,81
Fiber-optic array– scanning
technology (FAST)
It involves deposition of nucleated cells on the surface of a large glass slide, with scanning of
cells positive for epithelial or tumor-specific antigens. Ultra-high-speed automated digital
microscopy using fiber-optic array scanning technology has been developed to detect CTCs
mounted directly on a slide that are labeled by antibodies with fluorescent conjugates.
82,83
Multiphoton intravital flow
cytometry
It detects CTCs tagged in vivo using injected fluorescent ligands as they flow through the
vasculature.
48
Functional based assays
Folate-conjugated
nanotubes and magnetic
uPA-conjugated
nanoparticles +
photoacoustic flow
cytometry assay
This assay has been validated in a mouse model. Most cancer cells express folate receptors
and high levels of the urokinase plasminogen activator (uPA) receptors. Thus, CTCs can be
dually targeted in vivo (in the bloodstream) with folate-conjugated nanotubes and magnetic
uPA-conjugated nanoparticles and subsequently detected with two-color photoacoustic flow
cytometry. Future studies on humans will inform whether this new platform can diagnose
tumor cell dissemination.
84
Molecular detection
RT-PCR It allows the analysis of expression of candidate genes specific to epithelial tumor cells by
mRNA evaluation, often combined with other enrichment techniques. It has high sensitivity.
Disadvantages include RNA degradation, false-positive results due to nonspecific
amplification, contaminations and pseudogenes; false negative results due to low expression
levels.
85-91
Enzyme-linked
immunosorbent spot
technology
Immunological assay based on the ELISA (identification and count of cells able to secrete
proteins like MUC1 and CK19 in short-term culture), after immunomagnetic depletion of
CD45+ cells. Disadvantages include: CTC isolation not possible, further analysis not available,
need of active protein secretion and technically challenging.
55-57
QuantiGene ViewRNA CTC
Platform
CTC is isolated by size; sample is prepared (fixed, baked, permeabilized and protease
digested) to enable RNA accessibility. Target RNA Probe Sets are hybridized followed by a
sequential hybridization of signal amplification and detection components. Once processed,
filters are transferred to a microscope slide for image processing and analysis.
92
CK19 mRNA Assay Assays targeting specific mRNAs are the most widely used alternative to immunological
assays to identify CTCs. In breast cancer, the CK19 mRNA has been most frequently used in
clinical studies. Many transcripts (e.g. encoding CK18, CK19, CK20, Mucin-1, prostate-specific
antigen and carcinoembryonic antigen), however, are also expressed at low levels in normal
blood and BM cells 93, so quantitative RT-PCR assays with validated cutoff values are required
to overcome this problem.
93
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which may be potential drug targets.
In addition, certain transcription factors (TF), including
TWIST1,  SNAIL1,  SLUG,  ZEB1,  and  FOXC2 can  induce
EMT in mammary epithelial cells and/or breast cancer cells99.
Moreover, blocking the expression of TWIST1 in the highly
metastatic  4T1  murine  mammary  cell  line  reduced  both
metastatic burden and the number of CTCs in mice bearing
xenograft mammary tumors, thus linking EMT, metastasis,
and the presence of CTCs99. These findings suggest that the
expression of epithelial-cell surface markers, such as EpCAM,
may not be optimal for detecting a heterogeneous population
of  CTCs including those with a  mesenchymal  phenotype.
Evidence  exists  that  EpCAM-negative  CTCs  might  have
undergone EMT54.
Raimondi et al.95 investigated the expression of EMT and
stem cell markers in CTCs from 92 metastatic breast cancer
patients.  CTCs  were  isolated  by  CELLection  Dynabeads
coated  with  the  monoclonal  antibody  toward  EpCAM.
Samples  positive  for  CTCs  presence  (CD45-/CK+)  were
evaluated for  the expression of  ER alpha,  HER2,  ALDH1,
vimentin,  and  fibronectin.  Samples  negative  for  CTCs
presence (CD45-/CK-) were also evaluated for the expression
of vimentin and fibronectin, used as markers of EMT. In 34%
of  patients,  they  detected  cells  with  negative  CK/CD45
expression  but  positive  expression  of  vimentin  and
fibronectin95. This mesenchymal phenotype is more common
for  the  basal-like  molecular  subtype  of  breast  cancer100.
However,  further  analysis  is  needed  to  classify  CTC
expression with known subtypes of breast cancer for both
validation and clinical relevance.
One  study  on  mRNA  analysis  shows  that  the  low
abundance of EpCAM expression is associated with increased
vimentin in basal-like breast cancer101. Another study further
demonstrated  dynamic  changes  in  epithel ial  and
mesenchymal composition in circulating breast cancer cells
with  mixed  probes  using  RNA  in  situ  hybridization,
particularly in CTC clusters. Although rare in the circulation
compared with single CTCs, CTC-clusters have 23 to 50-fold
increased metastatic potential. CTC clusters are oligoclonal
in origin, derived from groupings of primary tumor cells that
together enter the circulation102. They can be captured via
several techiniques such as microfluidic devices, including a
specifically  designed  cluster  chip  which  operates  at  sub-
physiological flow rates, preventing these highly deformable
cell  groupings from squeezing through small  pores under
higher flow pressures103, direct precipitation of all blood cells
onto  specially  prepared  slides,  followed  by  high-speed
microscopic  scanning104,  as  well  as  enrichment  based
techniques105,106.
Claudin-low tumor cells
The most  commonly used markers  to  identify  carcinoma
cells  are  cytokeratins,  which  have  become  a  standard
detection marker for CTCs56,57,93,107.  Since hematopoietic
cells  rarely  express  cytokeratin  proteins  detectable  by
immunostaining108,109, specific detection can be achieved for
cells from epithelial tumors, such as breast carcinomas from
blood cells. However, if tumor cells undergo EMT to migrate
and  invade  the  body,  the  cytoskeleton  is  rearranged  and
epithelial  markers  such  as  E-cadherin,  claudins,  and
cytokeratins are downregulation110. Many detection methods
using cytokeratin antibodies are not able to detect all CTCs
secondary to this downregulation111. If indeed not all CTCs
are  detected  by  the  common  detection  methods,  false-
negative results would hamper the clinical implementation of
CTCs as a diagnostic marker. To improve CTC detection of
claudin low tumors, the use of CD146 and CD49f as selection
markers has been shown to improve detection of those cell
lines  showing  EMT-features112.  Our  group  has  recently
demonstrated that EpCAM based capture of CTC mimics
using a panel of ten cell lines recovered all intrinsic subtypes
of  breast  cancer  except  the  claudin-low  group2 3 .
Furthermore,  detection  techniques  not  dependent  on
epithelial markers may be used for detection of these cells, see
Table 1.
Apoptotic CTCs
As  tumors  increases  in  volume,  so  too  does  the  cellular
turnover and hence the number of apoptotic and necrotic
cells.  Under normal physiologic circumstances,  apoptotic
and  necrotic  cellular  remains  are  cleared  by  infiltrating
phagocytes. In theory this does not happen efficiently within
the  tumoral  mass,  leading  to  CTC  escape  as  well  as  the
accumulation of cellular debris and its inevitable release into
the circulation(ctDNA)113,114.
Although  many  CTCs  migrate  early  from  the  primary
tumor into the circulation, many may be cleared within a few
days115.  According  to  the  seed  and  soil  hypothesis,  the
survival of these cells depends on their distinctive biologic
characteristics  as  well  as  on the microenvironment at  the
secondary site116. Only rare subsets of cells finally succeed in
establishing  a  cross-talk  with  stromal  cells  in  secondary
organs that promotes tumor cell survival, angiogenesis, and
metastatic outgrowth. This could be related to the induction
of senescence in CTCs, to a low proliferative potential, or to
the presence of  apoptotic cells.  Mehes et  al.117  first  noted
apoptotic  cells  significantly  contribute  to  the  circulating
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tumor  cell  fraction  in  breast  cancer  patients  after  he
performed a  detailed microscopic  analysis.  An "inclusion
type" cytokeratin staining pattern and nuclear condensation
indicated  apoptosis  in  the  CTCs  isolated.  Furthermore,
apoptosis-related DNA strand breaks could be demonstrated
by applying the TdT-uridine nick end labeling assay in these
cells117. The monoclonal antibody targeting the neoepitope
M30, revealed by caspase cleavage of CK18 in early apoptosis,
has also been shown to be a marker for apoptotic CTCs118.
Kallergi et al.119 noted the presence of exclusively apoptotic
CTCs  in  a  patient  may  represent  a  favorable  prognostic
factor,  whereas  the  preponderance  of  proliferating  cells
(determined  by  Ki-67)  could  be  related  to  poor  patient
outcome  in  breast  cancer.  The  median  percentage  of
apoptotic CTCs per patient in his study was lower in patients
with  advanced  disease  compared  with  those  with  early
disease. Adjuvant chemotherapy reduced both the number of
CTCs per  patient  and the  number  of  proliferating  CTCs.
Kallergi et al.119 concluded that the detection of CTCs that
survive  despite  adjuvant  therapy  implies  that  CTC
elimination should be attempted using agents targeting their
distinctive molecular characteristics.
CTC enumeration clinical trials
Numerous studies including Bidard et al.12 pooled analysis
reveal  that  CTC  count  is  independently  prognostic  of
progression-free survival and overall survival in metastatic
breast cancer (MBC) patients120. Other trials by Lucci et al.9
and  a  meta  analysis  by  Zhang  et  al.10  have  further
demonstrated CTC detection is prognostic in non-metastatic
breast cancer as well11.
Additionally,  The Southwest  Oncology group (SWOG)
completed a prospective clinical trial (SO500) to evaluate the
utility  in changing therapy versus maintaining therapy in
MBC patients who have elevated CTCs after one cycle of a
new first-line chemotherapy121.  Although CTC status was
prognostic, simple enumeration did not predict for a benefit
in switching to an alternate cytotoxic therapy, likely because
simple enumeration has a low predictive value and cannot
predict a specific course of treatment. Other limitations to
this  trial  include  chemo/cross  resistance  and  statistical
limitations.
The  early  DETECT  trials  revealed  that  serial  CTC
measurements before and after chemotherapy are prognostic
and  can  be  used  to  monitor  treatment  benefit122,123.
Subsequent trials  being conducted by the DETECT study
group are evaluating targeted agents based on phenotypes of
CTC in patients with MBC124. To fully realize the potential of
CTCs  as  a  useful  biomarker,  simple  enumeration  is  not
sufficient.  Detailed  molecular  profiling  of  CTCs must  be
performed to inform the discovery of therapeutic predictors
and  actionable  targets,  important  steps  forward  in
personalizing medicine.
CTC molecular profiling
Several mechanisms exist to profile CTCs including protein
expression,  genomic,  gene  expression  and  functional
characterization125,126. They have been cultured in vitro, used
in xenotransplantation in vivo16,127, and assessed using next-
generation sequencing (NGS)16,17. Several studies have shown
that  recurrent/metastatic  breast  tumors  and  CTCs  show
discordance in hormone receptors (ER and PR) and HER2
expression from the primary tumor112,128-130. Furthermore,
patients with TNBC do not have identified targeted therapies
and are currently treated by chemotherapy alone and have
very  limited  treatment  options  upon  distant  metastasis.
Therefore, comparing genomic alterations in cancer-related
genes between primary, metastatic breast tumors and CTCs
and  may  provide  insights  into  mechanisms  of  tumor
metastases and drug resistance that may help guide targeted
therapeutics131. Recent technical advancements in massively
parallel or high-throughput NGS offer multigene mutational
profiling that provides comprehensive genetic information
on breast cancer molecular pathology, paving the road for
newer and more effective  therapeutic  targets131.  NGS has
changed the perspective on genome profiling,  since DNA
sequencing has the potential to identify structural changes,
including gene fusions and even point mutations, in addition
to copy number. Furthermore, NGS using RNA Seq would
permit  full  genomic  and  transcriptomic  profiling,
maximizing the ability to study individual genes, pathway
perturbations, and chromosomal losses/gains. Additionally,
NGS panels for inherited cancer has increased the potential
to  identify  pathogenic  variants  in  genes  that  would  not
typically have been tested (in breast cancer, genes other than
BRCA1/2)  and  to  offer  more  tailored  preventative
management  to  patients  and  family  members132.  Each
sequencing  technique  has  specific  advantages  and
disadvantages (Table 2)133-144.
In addition there are a variety of NGS platforms available
including second generation, sequencing of an ensemble of
DNA molecules with wash-and-scan techniques and third
generation, sequencing single DNA molecules without the
need  to  halt  between  read  steps,  whether  enzymatic  or
otherwise145 (Table 3)136,146-160.
The advantages of sequencing CTCs include: (1) the ability
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to  fully  sequence  large  numbers  of  genes  (hundreds  to
thousands) in a single blood test and simultaneously detect
deletions, insertions, copy number variations, translocations,
fusion events and exome-wide base substitutions (including
known "hot-spot mutations") in all  known cancer-related
genes in a cell(s) most likely to cause metastases, which may
be important for predicting response to select therapies; (2)
results from sequencing are presented as either positive or
negative  and  do  not  appear  as  gradations  as  with
immunofluorescence;  (3)  analysis  can  be  automated  to
reduce interpreter bias; and (4) allows us to evaluate tumor
heterogeneity161.
Molecular profiling of CTCs has been shown to predict
response and or resistance to therapy. RNA sequencing via
CTC-iChip  revealed  activating  mutations  in  PIK3CA,
FGFR2, and ESR-1 in breast cancer patients. Drug sensitivity
testing  revealed  that  the  selective  estrogen  receptor
modulators  (SERMs)  tamoxifen  and  raloxifene,  and  the
selective ER degrader (SERD) fulvestrant, were ineffective in
ESR-1 mutant cells, either alone or in the clinically approved
combination with inhibitors of the phosphatidylinositol 3-
kinase-mammalian  target  of  rapamycin  (PI3K-mTOR)
pathway (everolimus). Cultured CTCs were highly sensitive
to the PIK3CA inhibitor BYL719 and the FGFR2 inhibitor
AZD4547127.
A trial conducted by Gradilone et al.162  revealed that in
MBC patients the presence of CTCs expressing multidrug-
resistance-related  proteins,  and  ALDH1,  is  predictive  of
response to chemotherapy. Liu et al.163 reported on a patient
affected by chemo-refractory metastatic HER2-positive breast
cancer receiving lapatinib. The detection and characterization
of CTCs was evaluated and depletion of the EGFR-positive
CTC pool in the blood was associated with tumor response,
whereas disease progression was related to a recurrence in
CTCs, indicating expression of EGFR may predict response
to lapatinib-based treatments.
Sequencing  techniques  also  have  several  disadvantages
including:  (1)  limitations  with  regards  to  sensitivity  that
make  single  cell  analysis  difficult164 ,165 ,  including
amplification bias166; and (2) leukocyte contamination which
may cause  false  positive/negative  results  due to  impaired
visualization  of  amplified  transcripts.  However,  several
groups  have  been  able  to  overcome  these  challenges  via
various techniques, such as micromanipulation, laser-capture
microdissection,  and  flow  cytometry  with  promising
results167,168. For instance Magbanua et al.169 demonstrated
that it is feasible to isolate CTCs away from hematopoietic
cells with high purity through immunomagnetic enrichment
followed by fluorescence activated cell sorting (IE-FACS) and
profile them via array comparative genomic hybridization
analysis. With newer amplification techniques such as whole
genome amplification, in combination with NGS and FACS,
some researchers have shown it is possible to profile copy
number in a single cell in various cancer types, including in
breast  cancer170-173.  Single  cell  analysis  has  identified
clinically  significant  genomic  disparity  between  primary
tumors and CTCs3,174-176 therefore analysis of CTCs in this
fashion  may  surmount  the  plaguing  concern  of  tumor
heterogeneity.
Table 2  Advantages and disadvantages of DNA sequencing
Method Basic technique Advantages Disadvantages Reference
Sanger-chain termination
method (first generation
sequencing)
Fluorescent dye-labeled
bases; DNA fragments
separated by capillary
electrophoresis
High sensitivity, gold
standard complete sequence
Very time consuming; cannot
detect deletions, translocations
or copy number changes
133-136
Pyrosequencing-sequencing
by synthesis method
Chemiluminescent detection;
DNA polymerase synthesizes
cDNA to a target template;
pyrophosphate release is
detected at each base
addition
More sensitive than Sanger;
provides % of mutated vs.
wild-type DNA; works well
with fragmented DNA
Short read length limits
technique to hot spots. Limited
accuracy at detecting changes
in homopolymer runs.
Scalability is limited compared
with other NGS methods
136-140
Allele-specific RT-PCR Primers span DNA sites of
interest and probes detect
specific mutations
Very high sensitivity widely
used for clinical testing for
oncogene mutations in CRC
and NSCLC
Scalability constraints limit
application to hot spots
136,141-143
RT-PCR melting curve
analysis
Heterogeneous DNA PCR
products melt at different
temperatures than
homogenous DNA/PCR
products
High sensitivity provides
percentage of mutated
versus wild-type DNA
Often difficult to resolve
differences in melt curves.
Difficult to standardize.
Multiplex capability is limited
136,144
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Table 3  Next-generation sequencing platforms
Device Method Generation Major uses Run time Length of reads Reference
Illumina Hi Seq
4000
Flow cell-based, reversible dye
termination and four-color optical
imaging
2nd WES WGS SNP
WTA
<1-3.5 days 2×150 bp 136,146-151
Roche 454 pyro-
sequencing GS
FLX+
Emulsion PCR with bead-based
pyro-sequencing and CCD light
imaging
2nd WGS WTA
Targeted Seq SNP
10 h Up to 1000 bp 136,146,151-
153
Life Technologies
SOLiD 5500xl
Sequential dinucleotide ligation;
flow cell-based four-color optical
imaging
2nd WES WGS SNP 6 days 2×60 bp 136,146,150,1
51,154
Life Tech-nologies
Ion Torrent PGM
Semi-conductor based nonoptical
detection; standard dNTP
sequencing chemistry
2nd Targeted panel
Demand Sequenc-
ing
<1 day 400 bp 136,151,155
Complete
Genomics CGA
platform
DNA nanoball arrays coupled with
combinatori-al probe anchor
ligation
2nd WGS Slow: weeks to
months
~70 bases 136,151,156
Pacific Biosciences
PacBioRSII
Zero-mode waveguide, individual
polymerase; single molecule
sequencing using fluorescent
dNTPs
3rd Long read, full
microbial genome
<1-6 h 10-15 kb 136,151,157,1
58
Seqll Heliscope True Single Molecule Sequencing,
massive parallel sequencing without
amplification
3rd Targeted WGS
WES WTA
~8 h 25-60 bp 136,151,156,1
59
Nanopore Minion Nanopore exonuclease sequencing,
no need for amplification
3rd Long read, full
microbial
1 min-48 h 230-300kb 160
Illumina Hi Seq
4000
Flow cell-based, reversible dye
termination and four-color optical
imaging
2nd WES WGS SNP
WTA
<1-3.5 days 2×150 bp 136,146-151
Roche 454 pyro-
sequencing GS
FLX+
Emulsion PCR with bead-based
pyro-sequencing and CCD light
imaging
2nd WGS WTA
Targeted Seq SNP
10 h Up to 1000 bp 136,146,151-
153
Life Technologies
SOLiD 5500xl
Sequential dinucleotide ligation;
flow cell-based four-color optical
imaging
2nd WES WGS SNP 6 days 2×60 bp 136,146,150,1
51,154
Life Tech-nologies
Ion Torrent PGM
Semi-conductor based nonoptical
detection; standard dNTP
sequencing chemistry
2nd Targeted panel
Demand Sequenc-
ing
<1 day 400 bp 136,151,155
Complete
Genomics CGA
platform
DNA nanoball arrays coupled with
combinatorial probe anchor ligation
2nd WGS Slow: weeks to
months
~70 bases 136,151,156
Pacific Biosciences
PacBioRSII
Zero-mode waveguide, individual
polymerase; single molecule
sequencing using fluorescent
dNTPs
3rd Long read, full
microbial genome
<1-6 h 10-15 kb 136,151,157,1
58
Seqll Heliscope True Single Molecule Sequencing,
massive parallel sequencing without
amplification
3rd Targeted WGS
WES WTA
~8 h 25-60 bp 136,151,156,1
59
Nanopore Minion Nanopore exonuclease sequencing,
no need for amplification
3rd Long read, full
microbial
1 min-48 h 230-300kb 160
CCD: charge-coupled device; NA: not applicable; NGS: next-generation sequencing; WES: whole exome sequencing; WGS: whole genome
sequencing; SNP: single nucleotide polymorphism; WTA: whole transcriptome analysis.
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Tumor heterogeneity
Tumor heterogeneity can exist within the same site of disease
or  between sites  of  disease177,178  and contamination with
adjacent normal tissue can lead to false negative results or
confound  successful  targeted  therap179.  As  Navin  and
Hicks168  pointed out, tumor heterogeneity exists in breast
cancer because the malignant cells often arise from ductal
tissue and are constrained by the duct structure until they
begin to invade surrounding stromal  tissue.  They exhibit
regions  of  growth,  regions  of  hypoxia  and  necrosis,  and
regions of interaction with blood vessels and lymph ducts.
Given these variable selection pressures, tumor cells within a
single mass are not identical180.  This  heterogeneity in the
molecular characterization of single cells,  including CTCs
could  potentially  identify  rare  driver  mutations  that  are
diluted  out  when  profiling  bulk  tumors,  including  their
stroma168. Navin et al.172 revealed that by comparing multiple
single-cell copy number profiles, they could provide highly
accurate  measures  of  genomic  heterogeneity  within solid
tumors.  Furthermore,  by  comparing  multiple  single-cell
profiles, they showed that it was possible to reconstruct the
evolutionary lineage of a tumor and understand its pattern of
progression.
In  addition,  Heitzer  et  al.181  has  described  a  CTC
sequencing approach for single-cell analysis, suggesting that
contamination with normal cells may be reduced. Secondly,
although the sequencing of CTCs does not change the fact
that  the  readout  is  still  at  the  level  of  the  genome,  we
anticipate that, especially in cases in which metastatic lesions
are inaccessible, CTC sequencing will strengthen conclusions
regarding mutations that are drivers versus those that are
passengers  as  they  may  be  present  not  only  in  the
primary/metastatic lesion but also in the cells that were able
to escape into the circulation. The conserved nature of these
mutations may suggest an important functional contribution
to disease  progression.  Heitzer  et  al.181  demonstrated the
sequencing of CTCs may identify relevant private mutations,
present  but  not  detected  in  tumor  tissue.  In  contrast  to
CTCs,  single  cell  analysis  is  not  possible  when evaluating
ctDNA as a biomarker.
CtDNA
Circulating DNA was first identified by Mandel and Metais182
in 1948 but no association with disease was hypothesized.
Only 30 years later, in 1977, Leon et al.183 found circulating
tumor DNA (ctDNA) in plasma of patients affected by lung
cancer.  Cell  free  DNA  (cfDNA)  was  identified  in  the
peripheral blood of healthy individuals however patients with
cancerous tumors have higher quantities  and detection is
associated with poorer prognosis4,184.  Due to reduced cell
turnover and more efficient removal of defective cells from
the circulation by phagocytes, the concentration of cfDNA is
lower in healthy individuals. CtDNA, or soluble nucleic acids
shed into the bloodstream in patients with cancer, are linked
to  apoptosis  and  necrosis  of  cancer  cells  in  the  tumor
microenvironment. Secretion within exosomes has also been
suggested as a potential source of cfDNA. The released tumor
cells are usually phagocytosed by macrophages which engulf
necrotic  cells  and  release  digested  DNA  into  the  tissue
environment185.  Additionally,  tumors  usually  harbor  a
mixture  of  different  cancer  cell  clones  that  justify  their
genomic and epigenomic heterogeneity, together with other
normal cell types, such as hematopoietic and stromal cells.
Thus, during tumor development and turnover both tumor-
derived and wild-type cfDNA can be released into the blood.
Consequently, the proportion of cfDNA that originates from
tumor  cells  varies  according  to  the  state  and  size  of  the
tumor.  The  amount  of  cfDNA  is  also  affected  by
physiological  factors  such  as  clearance,  degradation  and
filtering events of the blood and lymphatic system. Nucleic
acids  have  a  half-life  in  the  circulation  ranging  from  15
minutes to several hours depending on the rate of clearance
from the blood by the spleen, liver and kidney186,187.
The  characteristics  of  ctDNA  suggest  they  are  in  part
derived from apoptotic cells. For instance, when the lengths
of ctDNA strands are measured, they often assume the classic
ladder  pattern  in  integer  multiples  of  180  base  pairs,
characteristic of the apoptotic process. In fact, most ctDNA
fragments  measure  between  180  and  200  base  pairs,
suggesting  that  apoptosis  likely  produces  the  majority  of
ctDNA in circulation113,114.
Pre-analytic considerations
Cell  lysis  can occur hours  after  venipuncture when using
standard tubes for blood collection, leading to an increase in
contaminating  cellular  DNA that  may  hinder  analysis  of
ctDNA.  This  normal  DNA  from  dying  blood  cells  will
contaminate the specimens and dilute ctDNA. This is  the
reason why plasma is recommended, since its analysis avoids
the simultaneous testing of material originally associated with
hematopoietic cells. However, centrifugation speed, amount
of blood collected, a delay in blood processing and storage
temperature  (contaminating  cells  can  be  removed  after
storage  at  -20°C)can  influence  the  amount  of  cfDNA
extracted from plasma187-189. Toro et al.190 conducted a study
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comparing the properties of two cell stabilizing reagents in
blood samples from MBC patients and measured genome
equivalents  of  plasma DNA by droplet  digital  PCR.  They
compared wild type PIK3CA genome equivalents and also
assayed  for  two  PIK3CA  hotspot  mutations,  E545K  and
H1047R. Their results demonstrated that blood stored for 7
days in BCT tubes did not show evidence of cell lysis, whereas
PAX gene tubes showed an order of magnitude increase in
genome  equivalents,  indicative  of  considerable  cellular
lysis190.  Several  kits  exist  for  DNA  extraction  with  some
recent studies comparing the kits. The QIAamp DNA Blood
Mini and Circulating Nucleic Acid kits from Qiagen (Hilden,
Germany)  gave  the  highest  recovery  of  cfDNA191,192.
Currently there is no uniform standardization and each study
has its own protocol regarding pre-analytical conditions for
processing specimens.
Furthermore, levels of cfDNA might reflect physiological
and  pathological  processes  that  are  not  tumor-specific.
CfDNA yields are higher in patients with malignant lesions
than in patients with resected tumors, but increased levels
have also been quantified in patients  with benign lesions,
inflammatory  diseases  and  tissue  trauma193.  Please  see
Table 4  for  the  advantages  and  limitations  of  CTCs  vs.
cfDNA5-20,113,114,183-187.
CfDNA detection and molecular profiling
Several sensitive techniques exist to detect such mutations in
cfDNA including droplet  digital  PCR (ddPCR)194,  CAPP-
Seq1 9 5  and  Guardant3601 9 6 ,  Sanger  sequencing1 9 7 ,
amplification  refractory  mutation  system  (ARMS)198,
pyrosequenc ing 1 9 9 ,  pyrophophoro lys i s -ac t iva ted
polymerization (PAP)200, tagged-amplicon deep sequencing
(TAM-Seq)201, beads, emulsion, amplification and magnetics
(BEAMing)202, modified semi-nested or nested methylation-
specific  PCR203,  utilization  of  microsatellite  biomarkers
followed by post-PCR product analysis using capillary array
electrophoresis204  among others.  It  is  possible to evaluate
nucleic acids for fusion events, copy number variants, indels,
and single nucleotide polymorphisms.
NGS has been developed to target the genome at various
scales  (whole  genome205,  whole  exome206,  and  targeted
panels207-209)  and  are  a  key  component  toward  realizing
personalized care in oncology.  A genome-wide screen for
copy  number  changes  has  the  advantage  that  it  is  an
untargeted  approach,  which  does  not  require  any  prior
knowledge  about  characteristics  of  the  primary  tumor
genome  or  its  metastatic  deposits.  Panel-based  targeted
sequencing of selected cancer genes or mutational hotspots is
a popular approach, and can generally be classified on the
basis of the target enrichment method used (e.g. amplicon
PCR versus hybridization capture), sequencing chemistry,
and scale of the sequencing platform. There is considerable
variability  across  targeted  NGS  panels  implemented  in
different clinical  laboratories in terms of the number and
identities  of  genes  tested,  and  sample  throughput.  The
number  of  genes  targeted  varies  depending  on  the
technology. Most vendor solutions are generally amplicon
PCR-based and target selected mutation hotspots in 1 to 50
cancer genes, and these include the Ion- Torrent AmpliSeq
(Life  Technologies,  Carlsbad,  CA)210,  and  the  Illumina
TruSeq Amplicon Cancer Panel (Illumina, San Diego, CA)207
among  others.  Targeted  enrichment  using  hybridization
capture  can  incorportate  more  genes  without  risk  a  of
problematic primer. Via a customized hybrization capture
technique the MSK-IMPACT panel targets 341 genes208,209.
Foundation  Medicine  targets  287  genes  (however  on,
formalin-fixed, paraffin-embedded (FFPE)tissue, use of these
genomic targets as a ctDNA assay is currently being validated
on clinicaltrials.gov protocol NCT02620527)211,212.
CtDNA clinical trials
Several trials clearly demonstrate that ctDNA is a specific and
highly sensitive biomarker in patients with MBC and non-
metastatic breast cancer4,213. Via molecular profiling of such
Table 4  Advantages and limitations of CTCs vs. cfDNA
Advantages Limitations
CTC Allows in depth assessment of viable metastatic tumor
cells, DNA, RNA, and protein; may reflect mechanisms of
resistance; may reflect treatment efficacy; allows
functionally analysis (in vitro/in vivo testing)
Few and fragile; requires sophisticated isolation techniques;
EMT may cause false negative results; tumor heterogeneity
within CTCs; unclear which CTCs cause metastases
Cell free cfDNA May reflect mechanisms of resistance; may reflect
treatment efficacy; sensitive biomarker; available from
other sources: urine, plasma, ascitic fluid
Present in inflammatory states and aging (not cancer
specific); contamination with DNA from lysed cells; unclear
if clinically relevant given being released from dying tumor
cells; predetermined somatic alterations need to be
identified; does not permit single cell analysis
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nucleic  acids,  researchers  have focused on targeting their
specific gene mutations and possibly explaining resistance to
chemotherapy in metastatic cancer214.
For instance, Schiavon et al.215 conducted a study on 171
breast cancer patients with advanced breast disease evaluating
ESR1 mutations by ultra high-sensitivity multiplex digital
polymerase chain reaction assaysin ctDNA. ESR1 mutations
were  found  to  be  a  major  mechanism  of  resistance  to
aromatase inhibitors, as evidenced by shorter progression-
free survival (PFS) in those patients with the mutation, and
more common in those with metastatic disease.
Additionally  in  the  BOLERO-2  trial,  Chandarlapaty  et
al.216  demonstrated that patients with the ESR1 mutation
D538G in ctDNA derived a 3.1 month PFS benefit from the
addition of everolimus (an mTOR inhibitor), whereas those
with the Y537S mutation showed stable PFS.
Additionally, it was demonstrated that persistent declines
in  the  levels  of  the  AKT1  E17K  mutation  in  ctDNA  is
associated  with  durable  tumor  regression  to  the  AKT
inhibitor AZD5363217.
Another trial assessing mutations in ctDNA as an indicator
of therapeutic resistance is the phase 3 BELLE 2 trial. PIK3CA
status in cfDNA predicted efficacy of the inhibitor buparlisib
in combination with fulvestrant in postmenopausal women
with endocrine resistant advanced breast cancer. In patients
with PIK3CA mutations identified by ctDNA, median PFS
was 7.0 months in patients treated with buparlisib vs.  3.2
months in those treated with placebo. In those with non-
mutant PIK3CA by liquid biopsy, there was no difference in
PFS218.
Murtaza et  al.206  presented an extensive comparison of
biopsy and plasma samples collected from a MBC patient
over  a  3-year  clinical  course,  in  which  whole  exome
sequencing (WES) and deep sequencing of plasma DNA and
tumor biopsies revealed resistance to targeted agents such as
lapatinib,  a  tyrosine kinase inhibitor of  EGFR (epidermal
growth factor receptor) and HER2. Thus deep sequencing of
plasma DNA, applied to selected samples with high tumor
burden in blood, may help identify the mutations associated
with drug resistance193,219.
The role of ctDNA in evaluating minimal residual disease
has also been evaluated by Schiavon et al.215 in a prospective
cohort of 55 early breast cancer patients in which detection of
ctDNA in plasma after completion of  apparently curative
treatment-either at a single postsurgical time point or with
serial follow-up plasma samples-predicted metastatic relapse
with high accuracy. The concept of tumor dormancy may in
part account for minimal residual disease in patients.
Tumor dormancy
Experimental biology studies have documented two types of
tumor dormancy: cellular dormancy with solitary cancer cells
held in cell-cycle arrest and micrometastatic dormancy with a
balanced state of apoptosis and proliferation220.  Dormant
CTCs appear to account for late disease recurrence even after
prolonged disease free survival in breast cancer221. CTCs are
detectable  in  as  many  as  one-third  of  patients  who  are
prolonged survivors222. Payne et al.223 confirmed the ability
to detect minimal residual disease in breast cancer patients by
assessing CTCs, DTCs and ctDNA. Shaw et al.224  revealed
that  copy  number  variations  (CNV)  detected  in  ctDNA,
mirror the primary tumor up to 12 years after diagnosis in
one-fifth  of  breast  cancer  patients.  SNP/CNV analysis  of
ctDNA was able to distinguish between patients with breast
cancer and healthy controls during routine follow-up. Given
these findings, the detection of minimal residual disease in
breast cancer via CTCs or ctDNA is possible, and molecular
profiling may be able to identify therapeutic targets in the
future.
Circulating exosomes
Exosomes  are  small  membrane  vesicles  (30-100  nm)
containing functional biomolecules (proteins, lipids, RNA
and DNA) that are released by most cell types upon fusion of
multivesicular  bodies  with  the  plasma  membrane,
presumably  as  a  vehicle  for  cell-free  intercellular
communication225. Circulating tumor derived exosomes were
demonstrated to prepare a favorable microenvironment at
future metastatic sites and mediate non-random patterns of
metastasis via vascular leakiness, stromal cell education at
organotropic sites, bone-marrow-derived cell education, and
recruitment  necessary  to  complete  pre-metastatic  niche
evolution226-228. Furthermore, exosomal DNA was found to
reflect  the  mutational  status  of  parental  tumor  cells.
Therefore future studies on exosomes as a biomarkers may be
useful  not only to predict  metastatic  propensity in breast
cancer229,  but  also  to  determine  organ  sites  of  future
metastasis227 and to monitor treatment response230.
Circulating microRNAs
MicroRNAs (miRs) are evolutionary conserved, small non-
coding  RNA  molecules  consisting  of  approximately  22
nucleotides.  One miR has binding affinity to hundreds of
different  mRNAs  and  hence,  miRs  are  involved  in  the
regulation of various cellular processes, such as development,
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differentiation, and proliferation231. MiRs are released into
the blood circulation by apoptotic and necrotic cells or active
secretion232.  They  can  exist  either  extracellularly,  in
association with Argonaut proteins, or in exosomes in the
blood circulation225.  To  date,  numerous  miRs  have  been
identified, and varied circulating miRs concentrations are
found  in  different  breast  cancer  subtypes  and  some  are
associated  with  prognosis  and  treatment  response233-235.
Given there is already quite a substantial literature in this
emerging field, miRs are beyond the scope of this review.
Circulating biomarker
characterization and clinical
implications
Detailed molecular profiling of tumors and circulating tumor
biomarkers  such  as  CTCs  and  ctDNA  has  already  been
changing the therapeutic landscape of cancer across several
cancer  types.  Currently  it  is  standard  clinical  practice  to
evaluate genetic alterations in many cancers. For instance, in
non-small  cell  lung cancer (NSCLC), the detection of the
somatic activating mutations in EGFR predicts for sensitivity
to EGFR inhibitors such as Tarceva49,236,237.  In melanoma,
the presence of BRAF V600E mutation predicts sensitivity to
BRAF inhibitors such as vemurafenib238. In colon cancer the
presence  of  KRAS  mutations  has  been  established  as  a
negative predictive marker for treatment with EGF receptor
(EGFR)  inhibitors239,240.  However,  unlike  drug  therapy
matched  somatic  mutations  in  NSCLC,  melanoma,  and
colon cancer,  drug  therapy  matched to  the  presence  of  a
somatic  mutation  has  yet  to  be  robustly  established  as  a
standard approach in breast cancer.
In breast cancer, mutations in the estrogen receptor ESR1
are  a  potential  driver  of  endocrine  resistance215,216,241.
Furthermore  multiple  alterations  in  genes  related  to  the
PI3K-mTOR  pathway  may  confer  re s i s tance  to
trastuzumab218,242. A recent trial in breast cancer established
a CTC PD-L1 assay  that  can be  used for  liquid biopsy  in
future  clinical  trials  for  stratification  and  monitoring  of
cancer patients undergoing immune checkpoint blockade243.
As  demonstrated  in  other  tumor  types  and  in  breast
cancer, a better understanding of mechanisms of treatment
resistance  and  biomarkers  to  predict  for  response  are
required  to  reduce  cancer  related  mortality.  The  key  to
standardizing the assessment of somatic mutations in breast
cancer  would  be  to  integrate  tumor,  CTCs  and  ctDNA
sequencing data into a systematic and broad-based plan with
clinical  endpoints.  Currently  there  are  several  trials
investigating  anti-HER2 therapies  in  patients  with  HER2
negative primary tumors, yet HER2 positive CTCs such as
the  DETECT  3  trial244,  evaluating  lapatinib,  CareMore-
Trastuzumab244  evaluating  trastuzumab,  a  monoclonal
antibody directed against HER2 in breast cancer and CirCe
TDM-1  evaluating  TDM-1,  trastuzumab  linked  to  the
cytotoxic agent DM-1245. Incorporating molecular profiling
of  CTCs/ctDNA  in  trials  such  as  Molecular  Analysis  for
Therapy Choice (MATCH), a genomic pre-screening study,
the  National  Cancer  Institute  (NCI)  aims  to  explore  the
efficacy of existing targeted agents against specific molecular
aberrations,  and to  evaluate  if  these  same therapies  have
comparable activities across different tumor subtypes246. One
challenge to  this  approach is  that  there  are  relatively  few
targeted therapies anticipated to be effective in some solid
tumors, such as breast cancer. NGS of circulating biomarkers
may help discover new potential rational targeted therapy
options.
Conclusions
Profiling primary tumor biology has led to many important
insights about the biology of breast cancer, yet relatively few
signatures predict treatment sensitivity. A critical barrier to
progress may be that MBC and the circulating cells leading to
macrometastasis are inherently different than primary breast
cancer. In contrast, primary tumors shed CTCs and cfDNA
into  the  systemic  circulation  where  they  are  subject  to
metastatic inefficiency and potentially after a period of tumor
dormancy may lead to macrometastases247,248. The ultimate
goal of detecting and molecularly characterizing CTCs and
ctDNA would be to shift the current clinical paradigm that
incorporates  relatively  few  prognostic/predictive  clinical
markers (estrogen receptor, progesterone receptor, HER2) to
a landscape in which clinicians could measure tumor biology
in real time by profiling CTCs or ctDNA in order to discover
therapeutic  targets,  detect  minimal  residual  disease,  and
predict response to treatment. In order to attain such a goal,
CTCs and ctDNA sequencing data must be integrated into
systematic and broad-based trials  with clinical  endpoints.
Several trials discussed in this paper strive toward this goal,
with the DETECT 3, BOLERO-2, BELLE 2 trials and others
focusing  on  this  very  concept  by  evaluating  therapeutic
response based on phenotypes of CTCs or ctDNA in patients
with  breast  cancer124,216,218.  In  summary,  once  further
established,  the  molecular  characterization of  circulating
biomarkers has the potential to provide the ideal mechanism
of  personalizing  treatment  in  breast  cancer  for  the  best
clinical results by predicting treatment response, evaluating
minimal  residual  disease  and  allowing  for  the  rational
selection of targeted therapies.
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